Why do these companies like AMRN give free stock to management in huge numbers and they turn around and sell them at market. That's in addition to their salary and bonus. These guys at AMRN are getting filthy rich selling their free stock. Why don't they at least hold the stock? BECAUSE THEY KNOW THERE IS NOTHING HERE!
I believe the recent price action is indicative of short term investors getting out due to the continuation of the REDUCE-IT trial. But common sense would dictate the chance of early cessation were very low. I think some consideration should be given to some 'hidden' facts about REDUCE IT that I don't think many have actually thought about with regards to the chances of it actually expanding the labeling for Vascepa. Consider this... When REDUCE IT was initiated, the official company projection for 60% and 100% of 'cardiovascular events' was indicated for 1st half of 2016 and 2nd half of 2017 respectively. Then in August 2016 they added the 80% analysis with projection of 1st half of 2017 and still had 100% in 2nd half of 2017. Now, in the last Press release, they expect the 100%, or the 1,612th event, to occur in early 2018. So it has the appearance that the projected timeframe for these 'cardiovascular events' has taken longer than initially projected, therefore, it provides a potential thought process that might give credence to the idea that the Vascepa arm of the study hasn't had the same frequency of events as the placebo arm. Of course, there's no way to know for sure but is it telling us that Vascepa may be responsible for slowing the rate of events? Isn't that what the study was designed to determine? Read back through the Press Releases and see how the projections have slowly moved further out than originally stated... not by a huge amount but it has been extended now into 2018. I definitely don't like the recent price action but also wonder if maybe there's hope hidden in the data being presented by the DMC in the latest release.
SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M /Undiscovered Stock/ Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Why were MERCK officers at AMRN headquarters at 5pm yesterday?
Long Island Iced Tea Looks Poised To Benefit From Shift Away From Carbonated Beverages
Long Island Iced Tea is a beverage company that provides premium non-alcoholic ready-to-drink iced tea bottle beverages. The company recently closed a public of
WHAT IS HAPPENING HERE. What kind of news could make this go bearish for an entire week?
All you have to do is click "holders" here on Yahoo for AMRN, then "insider transactions". Insiders are selling like crazy, every chance they get. What does that tell you? Scam stock! Statistics don't lie.
The price action is telling us the market is somewhere between 65% and 85% sure that Reduce-It is a bust. Is that the general belief here?
AMRN, looks to be overvalued at this price Ive been struggling with this stock lately. Some of my other trades have been from Awe-Som.e.Sto-cks. which are working out pretty well.
Shareholders of the micro-cap Amarin have financed one of the largest, longest, and most expensive drug studies in the history of medicine. It will be an extreme bummer if it was all a waste of money. That would be akin to a minimum wage employee going all-in for a Porche 911 and crashing it on the way home from the show-room, before insurance had been purchased!
I realize we can't help ourselves but don't you just hate being an AMRN shareholder! This is more like Extreme Lotto playring than anything close to investing!
Nice move started about noon (up 20 cents on above average volume). Good sign going into a weekend, especially with the North Korea thing dragging on the market.
still working on the hypothesis that the 80% peek will be positive; why else would they have added the second interim event?
popping to $4 was predictable after that earnings call.....but retreating back to $3.65? Profit taking for sure but that is quite a large percentage. I still think she gets back up to the $4's by weeks end. IMHO of course. Good job on the sales numbers Amarin....impressive.
almost tripling sales reps. highly optimistic on AMRN
Looks like a 1.2 million share buy according to the chart. Maybe this goes up!
No posts on this board today? Wow.... not good. Thinking of getting back in here though.
The hype has worn off and things are dropping out. That does not change the great look of this stock's possibility. Now is probably a great time to buy before it rallies, but I will be waiting until the exact moment this starts to move back in the green before I drop another $1500 on it
the test results are excellent. endorsement by Pawn Stars. This will be 15 dollar stock within one year.
Secondary pricing? Anyone?
can anyone tell me what this company's monthly cash burn is? looks like they have about $85mil in the bank as of the end of June. Just trying to assess potential for dilution.